We thank Dr Rudometkin and colleagues for their complimentary remarks regarding the conduct of our study and our article.1 With regard to the concomitant use of antimetabolites, we chose not to taper antimetabolite therapy for patients who were receiving these medications when they entered the study unless there was a specific medical reason to do so. Patients who began receiving infliximab as monotherapy were either intolerant of or refused adjunctive treatment with conventional systemic immunosuppressive agents, although all of the patients had been treated with previous regimens of immunosuppression that included corticosteroids and at least 1 other immunosuppressive agent as a prerequisite for participating in our study. As the respondents note, our rationale for the continuation of antimetabolite therapy was to lessen the formation of anti-idiotypic antibodies to infliximab. However, it is also noteworthy that infliximab has appeared to be safe and efficacious as a monotherapeutic agent in other trials for different systemic inflammatory diseases.2,3